If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Search Tips:- A product is required in combination with specific keywords in order to retrieve scientific content
- Refer to Our Medications to ensure correct spelling of the product you are looking for
- Please note that keywords are required to be entered in English
- Use exact words rather than broad terms
Medsafe has granted Paxlovid™ (nirmatrelvir/ritonavir tablets) provisional consent for the treatment of coronavirus disease 2019 (COVID-19) in adults 18 years of age and older, who do not require initiation of supplemental oxygen due to COVID-19 and are at increased risk of progression to hospitalisation or death.
Paxlovid™ (nirmatrelvir/ritonavir)
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Search Tips:- A product is required in combination with specific keywords in order to retrieve scientific content
- Refer to Our Medications to ensure correct spelling of the product you are looking for
- Please note that keywords are required to be entered in English
- Use exact words rather than broad terms
Paxlovid™ Quick Finder
*Contact Medical Information. 11AM-7PM NZST Monday to Friday; excluding Australian National and NSW Public Holidays.
Submit a medical question for Pfizer prescription products.